Safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in hepatitis C virus/human immunodeficiency virus co-infected patients

Table 1 Demographic characteristics of the patients at baseline n (%)

Characteristic	Ledipasvir/sofosbuvir for 12 wk (n = 40)
Median age (IQR) - yr	53 (51-57)
Male sex	25 (62.5)
Race1
White	13 (32.5)
Black	22 (55.0)
Asian	1 (2.5)
Other or unknown	4 (10.0)
Mean body-mass index (IQR)2	26.2 (22.7-28.7)
Smoking	13 (32.5)
HCV genotype
1a	34 (85.0)
1b	5 (12.5)
3a	1 (2.5)
Baseline HCV RNA (IQR), log10 IU/mL	6.3 (6.0-6.6)
HCV RNA > 6 million IU/mL	5 (12.5)
Cirrhosis	10 (25.0)
Baseline creatinine, mean (range), mg/dL	0.95 (0.56-1.48)
Baseline eGFR, mean (range), mL/min	90.0 (52-134)
CD4, cells/mm3
< 200	1 (2.5)
200-350	7 (17.5)
> 350	32 (80)
Mean CD4+ cell count (IQR), cells/μL	638 (366-857)
Antiviral regimen	40 (100)
HCV treatment history
No previous treatment	31 (77.5)
Previous treatment	9 (22.5)

¹Self-reported;

²Calculated as weight in kilograms divided by height in meters squared. BMI: Body mass index; eGFR: Estimated glomerular filtration rate; HCV: Hepatitis C virus; IQR: Interquartile range.